The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple myeloma patient outcomes and advancing…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new…
The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first…
Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish…
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…
Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…
